Cytochrome P450 polymorphisms and response to antipsychotic therapy

Pharmacogenomics

Volumn 3, Issue 2, 2002, Pages 201-218

  Scordo, Maria Gabriella ^a   Spina, Edoardo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antipsychotic drugs; CYP1A2; CYP2D6; CYP3A4; Extrapyramidal side effects; Genetic polymorphism; Genotyping; Metabolism; Pharmacogenetics; Phenotyping; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BUTYROPHENONE; CARBAMAZEPINE; CHLORPROMAZINE; CIPROFLOXACIN; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; ITRACONAZOLE; NEFAZODONE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; THIOXANTHENE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AMNESIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG TOXICITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GENOTYPE; HUMAN; HYPERPROLACTINEMIA; LIPOPHILICITY; PARKINSONISM; PHENOTYPE; PREDICTION; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SOMNOLENCE; STEADY STATE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS;

EID: 0036119445     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.2.201     Document Type: Review

References (146)

1. Enzymatic oxidation of xenobiotic chemicals
2. Drugs in special patient group: Clinical importance of genetics in drug effects
3. Active metabolites of neuroleptic drugs: Possible contribution to therapeutic and toxic effects
4. The metabolism of atypical antipsychotic drugs: An update
5. Human cytochrome P450: Problems and prospects
6. Human cytochrome P450 enzymes
7. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
8. Metabolic polyporphisms
9. Inter-individual and inter-ethnic differences in polymorphic drug oxidation. Implication for drug therapy with focus on psychoactive drugs
10. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors
11. Inhibition and induction of cytochrome P450 and the clinical implications
12. The molecular basis of genetic polymorphisms of drug metabolism
13. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
14. Racial and gender differences in N-acetyltransferase, xanthine oxidase and CYP1A2 activity
15. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
16. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans
17. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
18. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population
19. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
20. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
21. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
22. Polymorphic hydroxylation of debrisoquine in man
23. Polymorphic hydroxylation of debrisoquine
24. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
25. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
26. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
27. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin
28. Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders
29. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
30. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
31. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
32. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
33. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
34. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
35. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
36. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
37. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
38. CYP2D6 genotype and antipsychotic-induced extrapyramidal side-effects in schizophrenic patients
39. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
40. Metabolism of phenothiazine and butyrophenone antipsychotic drugs: A review of some recent research findings and clinical implications
41. Metabolism, pharmacogenetics and metabolic drug-drug interactions of antipsychotic drugs
42. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes
43. Thioridazine cardiotoxicity
44. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype
45. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin
46. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
47. Metabolism and pharmacokinetics of antipsychotic drugs
48. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
49. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism
50. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol
51. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo
52. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine
53. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
54. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol
55. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
56. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
57. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
58. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications
59. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
60. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
61. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population. Psychia
62. CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients
63. Effects of smoking, CYP2D6 genotype and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients
64. Plasma concentrations of haloperidol and its reduced metabolite are related to the CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
65. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
66. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism
67. Coadministration of fluvoxamine increases serum concentrations of haloperidol
68. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients
69. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
70. Drug metabolism and atypical antipsychotics
71. The metabolism of atypical antipsychotic drug: An update
72. Elevated levels of clozapine in serum after addition of fluvoxamine
73. Extrapyramidal symptoms after addition of fluvoxamine to clozapine
74. Pharmacokinetic interaction of clozapine with selective serotonin re-uptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
75. Clozapine and fluvoxamine, a curious complexity
76. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
77. Influence of plasma related variables on clozapine levels
78. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: Effect of smoking
79. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C → A polymorphism in Intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine
80. Serum concentrations of clozapine and its metabolites: Effects of cotreatment with fluoxetine or valproate
81. Serum levels of clozapine and norclozapine in patients treated with selective serotonin re-uptake inhibitors
82. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
83. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6
84. Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes
85. Metabolism and bioactivation of clozapine by human liver in vitro
86. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine Br.
87. Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms
88. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline
89. Seizure following addition of erythromycin to clozapine therapy
90. Erythromycin-induced clozapine toxic reaction
91. Absence of interaction between erythromycin and a single dose of clozapine
92. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole
93. The effect of nefazodone on clozapine plasma concentrations
94. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
95. Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
96. Biotransformation of post-clozapine antipsychotics: Pharmacological implications
97. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine
98. Interaction of olanzapine with fluvoxamine
99. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations
100. Olanzapine: Pharmacokinetic and pharmacodynamic profile
101. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanisms
102. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
103. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic
104. Quetiapine: A review of its safety in the management of schizophrenia
105. Absorption, metabolism and excretion of risperidone in humans
106. The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat
107. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedeberg's
108. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
109. Serum concentrations and side effects in psychiatric patients during risperidone therapy
110. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
111. Risperidone metabolism and the impact of being a cytochrome p450 2D6 ultrarapid metabolizer
112. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity
113. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine
114. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction
115. Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valporate
116. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia
117. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes
118. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
119. The effects of ketoconazole on ziprasidone pharmacokinetics: A placebo-controlled crossover study in healthy volunteers
120. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers
121. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes
122. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients
123. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia
124. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation
125. Frequency of CYP2D6 genotypes in schizophrenic patients and relation to antipsychotic therapy
126. Pharmacogenetics of classical and new antipsychotic drugs
127. CYP2D6 mutations and therapeutic outcome in schizophrenic patients
128. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects
129. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions
130. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type
131. NMS and genetic drug oxidation
132. Cytochrome P450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome
133. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity
134. CYP2D6 Hha I genotype and the neuroleptic malignant syndrome
135. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
136. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
137. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
138. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
139. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
140. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients
141. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
142. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure and abnormal involuntary movement scale (AIMS) score
143. Study of the association between cytochrome P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia
144. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
145. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
146. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia